Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab

Shibayama, Yui; Kameda, Hiraku; Ota, Shoichiro; Tsuchida, Kazuhisa; Cho, Kyu Yong; Nakamura, Akinobu; Miyoshi, Hideaki; Atsumi, Tatsuya

Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab

Shibayama, Yui; Kameda, Hiraku; Ota, Shoichiro et al.

Journal of diabetes investigation, 2019, 10(5), 1385-1387

Permalink : https://hdl.handle.net/2115/75841

このアイテムのアクセス数:698件（2026-08-08 09:56 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1111/jdi.13022			34

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/75841
タイトル	Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab
著者	Shibayama, Yui ; Kameda, Hiraku ; Ota, Shoichiro ; Tsuchida, Kazuhisa ; Cho, Kyu Yong ; Nakamura, Akinobu ; Miyoshi, Hideaki ; Atsumi, Tatsuya
著者名 Shibayama, Yui
著者名 Kameda, Hiraku
著者名 Ota, Shoichiro
著者名 Tsuchida, Kazuhisa
著者名 Cho, Kyu Yong
e-Rad_Researcher 70552420 著者名 Nakamura, Akinobu
e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
言語	英語
キーワード	Anti-programmed death-ligand 1 antibody
	Fulminant type 1 diabetes
	Immune-related adverse events
発行日	2019-09
出版者	John Wiley & Sons
収録物名	Journal of diabetes investigation
巻(号)	10(5)
ページ	1385-1387
抄録	With the expansive use of immune checkpoint inhibitors, the frequency of immune-related adverse events, including autoimmune type 1 diabetes, has been exponentially increased. The anti-programmed death-ligand 1 antibody, avelumab, has recently been approved for metastatic Merkel cell carcinoma therapy. Here, we report a patient that developed fulminant type 1 diabetes during avelumab treatment. An 81-year-old woman with no history of diabetes received avelumab for metastatic Merkel cell carcinoma. Elevated plasma glucose level (483 mg/dL), hemoglobin A1c level (7.5%) and ketosis were observed after 10 courses of avelumab without any symptoms related to hyperglycemia. As the laboratory tests showed insulin depletion, we diagnosed her with fulminant type 1 diabetes induced by avelumab. This is the first reported case of avelumab-induced type 1 diabetes, illustrating the necessity for close monitoring of glycemic control during avelumab therapy, as well as other immune checkpoint inhibitors.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	2040-1116
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1111/jdi.13022